Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Structure Therapeutics Inc. is a biopharmaceutical company engaged in the discovery and development of innovative therapies aimed at treating serious human diseases. The primary focus of Structure Therapeutics Inc. is on the structural biology-based approach to discover novel small molecule drugs, particularly in the field of G protein-coupled receptors (GPCRs). These receptors are critical elements in various physiological processes, making them significant drug targets for numerous challenging ailments, including metabolic, cardiovascular, and neurological disorders. The company's unique approach involves leveraging cutting-edge technologies to decipher the complex structures of GPCRs, which aids in the design of more effective and efficient therapeutic solutions. By harnessing the power of structural biology, Structure Therapeutics Inc. aims to address unmet medical needs, potentially transforming treatment protocols in key healthcare sectors. As an emerging entity in the pharmaceutical landscape, it plays a crucial role in advancing drug discovery methodologies and fostering collaboration across scientific and medical communities to improve patient outcomes.
$48.25
+$0.09 (+0.19%)
EOD Jun 25, 2026 · Twelve Data
Negative free cash flow of -$226M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$0.00
Net Income (TTM)
-$170M
▼ -15.2% YoY
Op. Margin
—
ROIC
-12.34%
▲ +6.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$159M
▼ -91.5% YoY
Op. Cash Flow (TTM)
-$34M
▼ -92.8% YoY
Net Debt
-$1.44B
Net Cash Position
Cash & Equiv.
$1.45B
Continue Research
Structure Therapeutics (GPCR)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Structure Therapeutics scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Structure Therapeutics scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -12.3% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh GPCR's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.